cat no | io1020
ioGlutamatergic Neurons PRKN R275W/R275W are opti‑ox™ precision reprogrammed glutamatergic neurons carrying a genetically engineered homozygous mutation in the PRKN gene encoding the Parkin protein. These cells offer a rapidly maturing, disease relevant and isogenic system for investigating the molecular and cellular significance of a homozygous R275W mutation in Parkinson’s disease.
Related disease model cells are available now with a heterozygous PRKN R275W mutation, and both can be used alongside their genetically matched control, ioGlutamatergic Neurons™.
Request a quote
Once your quote request has been submitted, one of our sales team will be in contact.
Unsure where to start?
Get in touch and we'll guide the way!
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the effect of homozygous expression of mutant Parkin protein on disease.
Scalable
With opti-ox technology, we can make billions of consistently reprogrammed cells, surpassing the demands of industrial workflows.
Quick
The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
Starting material
Human iPSC line
Karyotype
Normal (46, XY)
Seeding compatibility
6, 12, 24, 48, 96 & 384 well plates
Shipping info
Dry ice
Donor
Caucasian adult male (skin fibroblast)
Vial size
Small: >1 x 106 viable cells
Quality control
Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)
Differentiation method
opti-ox cellular reprogramming
Recommended seeding density
30,000 cells/cm2
User storage
LN2 or -150°C
Format
Cryopreserved cells
Genetic modification
Homozygous R275W missense mutation in the PRKN gene
Applications
Parkinson's disease research
Drug discovery and development
Disease modelling
Product use
ioCells are for research use only
ioGlutamatergic Neurons PRKN R275W/R275W are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a three-phase process: Induction, which is carried out at bit.bio (Phase 0), Stabilisation for 4 days (Phase 1), and Maintenance (Phase 2) during which the ioGlutamatergic Neurons PRKN R275W/R275W mature. Phases 1 and 2 after revival of cells are carried out by the customer.
ioGlutamatergic Neurons PRKN R275W/R275W are compatible with plates ranging from 6 to 384 wells and are available in two vial sizes, tailored to suit your experimental needs with minimal waste.
The recommended seeding density is 30,000 cells/cm2, compared to up to 500,000 cells/cm2 for other available products on the market.
One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plate. One Large vial can plate a minimum of 3.6 x 24-well plate, 5.4 x 96-well plate, or 7.75 x 384-well plates.
Madeleine Garrett | Field Application Specialist | bit.bio
2023
V1
Charles River & bit.bio
2022
V1
Charles River & bit.bio
2022
Charles River
Dr Kaiser Karim | Scientist
bit.bio
Dr Kaiser Karim | Scientist
bit.bio
Dr Marijn Vlaming | Head of Biology
Charles River
Read this blog to find out how experts from across academia and industry are approaching the challenges of reproducibility of in vitro cell models as well as potential solutions.
Further your disease research by pairing our wild type cells with isogenic disease models.